Q-omics provides the consensus-scored HS3ST5 profile across patient tissues and cancer cell-line models. HS3ST5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, HS3ST5 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, HS3ST5 RNA expression shows 15,148 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, KIRC, and TGCT as cancer lineages where HS3ST5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HS3ST5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HS3ST5 survival associations across molecular data types. HS3ST5 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HS3ST5 RNA expression–survival associations across cancer types. High HS3ST5 expression shows unfavorable associations in LIHC, ACC and STAD, but favorable associations in UVM, KIRP and LUSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for HS3ST5 RNA expression.
This table summarizes HS3ST5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HS3ST5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HS3ST5 shows lower tumor expression in KIRC, COAD, KICH and PRAD and higher tumor expression in UCEC and BRCA. The KIRC box plot shows higher HS3ST5 RNA expression in normal versus tumor tissue (log2 FC = −0.404, t-test p < 0.001).
This table shows molecular features associated with HS3ST5 in patient tissues and cancer cell lines. In patient samples, HS3ST5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HS3ST5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
